t
AstraZeneca PLC announced its total voting rights on 01 June 2026. As at 31 May 2026, the company's issued share capital with voting rights totalled 1,551,009,750 ordinary shares of US$0.25, with no shares held in Treasury, resulting in 1,551,009,750 total voting rights.
| Date | 1 Jun 2026 |
| Time | 15:00:00 |
| Category | Capital structure |
| ID | 4603G |
1 June 2026
Total Voting Rights
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 May 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,009,750 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,009,750.
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC